ET"s IG put an interesting report on insectidice india.Liked it a lot so read it and decide accordingly.
Scripscan:Insecticides India
Cmp:57
Target:75
Duration:6-9 months
Traded in:Nse-Bse
Introduction:Insecticides India is a relatively new player in the agro-chemical and house pesticides segment. It manufactures and distributes a range of crop protection and pest control products in the domestic market . It competes with multinational peers like Clariant , Monsanto Chemicals and Bayer, besides leading homegrown players including United Phosphorus, Rallis and Excel Crop Care.It is on the verge of emerging as a fully integrated player in the agrochemicals business, which makes it an interesting long-term pick.
BACKGROUND: Insecticides India started its journey several years ago by entering into a technical collaboration with US major Amvac, whose brand Thimet is now among the more well-accepted generic pesticides in the country. Subsequently, it tied up with Vanguard of the US to market its agro-chemicals products in India.The company has also acquired three well-known pesticide brands, including Tractor, from Montari Industries. Its plant in Jammu & Kashmir (J&K ) enjoys tax advantage, which makes it more cost-competitive compared to its peers. The Rs 250-crore company took a major leap last year, when it came out with its maiden public offer. It raised around Rs 36 crore from the primary market to fund its growth plans.
Expansion:It is on track to expand its manufacturing capabilities in two phases. Under the first phase of its capex plan, the company has set up a formulations manufacturing unit in J&K at a total cost of Rs 15 crore. Its capacity has now increased to 7,000 tonnes per annum for granules, 1,000 tonnes per annum for wetable dispensable powder and 10 lakh litres for concentrates.It has started work on the second phase of its expansion at Dahej for manufacturing specialised chemicals, besides setting up an R&D centre. A part of the second phase includes further expansion of its unit in J&K . The successful completion of the second phase will make Insecticides India a fully integrated player in its segment.
FINANCIALS: Insecticides India’s net sales during the June ’08 quarter nearly doubled to Rs 85.7 crore, compared to the corresponding period last year. Commissioning of the J&K formulations plant was a major boost. The tax-free unit helped the company to improve its operating margin to 9.3% of net sales in June ’08, against 7% a year ago. Better margins helped the company treble its net profit to Rs 6.2 crore in the first quarter, from around Rs 2 crore a year ago.As the company is in the crop-protection business, the June and September quarters are traditionally the strongest due to sowing of paddy, cotton and sugarcane. In the past three years, the company’s net sales have more than doubled, while net profit jumped by two-and-a-half times.
Conclusion: On an equity base of Rs 12.7 crore, its Q1 net profit translated into EPS of Rs 4.88. At the current market price of around Rs 57, the stock is valued at 2.8 times its estimated EPS for FY08 of nearly Rs 20 per share.This is much lower than its historical P/E of 4 and the industry’s average ratio of 7.The company is set to continue growing its topline and improve its profitability, thanks to its J&K unit and the second phase of expansion. There is limited downside risk in the stock at its current price and long-term investors can accumulate it.
Regards,
ARUN
I can be reached at:-arunanalyst@rediffmail.com
Please note
Note: The artciles are not research reports but assimilation of information available on public domain and it should not be treated as a research report.
Registration status with SEBI: I am not registered with SEBI under the (Research Analyst) regulations 2014 and as per clarifications provided by SEBI: “Any person who makes recommendation or offers an opinion concerning securities or public offers only through public media is not required to obtain registration as research analyst under RA Regulations”
Disclosure: It is safe to assume that I might have the dkiscussed companies in my portfolio and hence my point of view can be biased.Readers should consult registered consultants before making any investments.
Registration status with SEBI: I am not registered with SEBI under the (Research Analyst) regulations 2014 and as per clarifications provided by SEBI: “Any person who makes recommendation or offers an opinion concerning securities or public offers only through public media is not required to obtain registration as research analyst under RA Regulations”
Disclosure: It is safe to assume that I might have the dkiscussed companies in my portfolio and hence my point of view can be biased.Readers should consult registered consultants before making any investments.

Tuesday, August 19, 2008
Important Disclaimer&Privacy policy
This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com
Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
